[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitaire Ziekenhuizen KU Leuven\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":677},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,234,0,25,[9,46,78,107,136,165,196,248,271,290,309,329,357,387,408,432,464,489,510,531,555,581,608,633,652],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100613749","lifestyle-intervention-to-improve-twin-pregnancy-outcomes-100613749",false,"NCT07270640","Lifestyle Intervention to Improve Twin Pregnancy Outcomes","Lifestyle Intervention to Improve Twin Pregnancy Outcomes: an Integrated Pilot Study for a Multicentric Randomized Controlled Trial","LIFETWIN","Inclusion Criteria:\n\n* Prior to any randomization or intervention, participants must have provided voluntary written informed consent.\n* Diagnosis of dichorionic twin pregnancies must align with the acceptance criteria.\n* Participants must be recruited before the 14th week of gestation.\n* Proficiency in Dutch, English, or French is required.-\n\nExclusion Criteria:\n\n* Participant has a history of pre-existing diseases or condition impacting their diet:\n\n  1. pre-gestational diabetes\n  2. severe heart disease,\n  3. chronic renal disease,\n  4. celiac disease,\n  5. inflammatory bowel disease,\n  6. post-bariatric surgery\n* Participant has a history of pre-existing diseases or conditions impacting their physical activity ability:\n\n  1. Chronic Obstructive Pulmonary Disease (COPD)\n  2. Severe Asthma.\n  3. Fibromyalgia\n  4. Osteoarthritis\n  5. Chronic Pain Syndromes\n  6. Spinal Cord Injuries.\n  7. Multiple Sclerosis (MS)\n  8. Parkinson's Disease\n  9. History of a Stroke\n  10. Drug resistance Epilepsy\n* Participants identified with mental vulnerabilities requiring specific care pathways by Born in Belgium (BIB) or local screening tool.\n* Participants with a History of Mental Health Disorders\n\n  1. Post-Traumatic Stress Disorder (PTSD)\n  2. Anxiety Disorders\n  3. Depressive Disorders\n  4. Bipolar Disorder\n  5. Obsessive-Compulsive Disorder (OCD)\n  6. Schizophrenia or schizoaffective disorder\n* Inability to give informed consent\n* No knowledge of Dutch, English or French\n* First trimester diagnosis of severe congenital anomaly in one or both twins\n* First trimester foetal demise of one or both twins\n* Rupture of membranes prior to recruitment\n* Participation in any other interventional Study","FEMALE","18 Years",{"count":21,"type":22},81,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial to is assess the benefits of holistic lifestyle interventions, including nutrition, physical activities, and mindfulness, aiming to reduce preterm birth in twins, potentially revolutionizing twin care globally.\n\nAn initial integrated pilot study is be conducted to assess and refine the intervention methods. The primary objective of the pilot study is to evaluate feasibility. If deemed feasible, the full study will be implemented, incorporating data from pilot study participants into the main study.\n\nObjective of the full study: To evaluate if a multi-component lifestyle extends gestational age at delivery by one week. Additional objective: to evaluate if the intervention positively influences multiple secondary outcomes including pregnancy complications, neonatal and maternal outcomes, and maternal quality of life.\n\nFor the pilot study, we aim to include 81 pregnant women across 4 sites. This sample size is based on pragmatic considerations, while ensuring diverse representation, including individuals from low socioeconomic status backgrounds and high-risk groups. For the full trial, in total 274 women are needed to detect a clinically meaningful difference in gestational age at delivery, the primary outcome.",[28],"Twin Pregnancy, Dichorionic",[30,31,32],"twin pregnancy","dichorionic","lifestyle interventions","RECRUITING","2026-08-13",{"date":36,"type":37},"2026-08-17","ACTUAL",{"date":39,"type":37},"2025-12-05",{"date":41,"type":22},"2027-06",{"name":43,"class":44},"Universitaire Ziekenhuizen KU Leuven","OTHER",4,{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100650776","the-tooth-collar-technique-100650776","NCT07753525","The Tooth Collar Technique","The Tooth Collar Technique (TCT): a Prospective Case Series on a Novel Flap Design for Ridge Augmentation","TCTechnique","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legal authorized representative has been obtained prior to any screening procedures\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Indication for horizontal and\u002For vertical bone augmentation in the maxilla or mandible in preparation for implant placement\n* Sufficient general health to undergo elective oral surgical procedures, as judgjed by the investigator\n* Ability and willingness to attend all study visits and comply with the protocol requirements.\n\nExclusion Criteria:\n\n* Current smoking or use of other nicotine-containing products (eg, e-cigarettes, chewing tobacco)\n* Presence of uncontrolled systemic diseases that may compromise healing\n* Ongoing chemotherapy, radiotherapy, or bisposphonate\u002Fanti-resorptive therapy in the head or neck region\n* History of radiation therapy to the jaws\n* active or untreated periodontal disease, caries or poor oral hygiene\n* Poorly fitting restorations on teeth adjacent to the augmentation site\n* Known allergy or hypersensitivity to any material used in the augmentation procedure.\n* Pregnant or breastfeeding women, or women planning pregnancy during the study period.\n* Participation in another interventional clinical study within the last 30 days\n* Any other condition or circumstance that, in the opinion of the investigator, could compromise participant safety, compliance, or the validity of the study results.\n* Participation in an interventional study with an investigational medicinal product or device.","ALL",{"count":56,"type":22},30,[25],"The aim of this study is to evaluate wound healing after the application of the Tooth Collar Technique (TCT) for bone augmentation in the upper or lower jaw. This technique is designed to promote tension-free wound closure and to reduce the risk of wound dehiscence. Augmentation is performed under local anesthesia. The gingiva is opened according to the TCT, after which the bone defect is reconstructed with standard biomaterials and covered with a membrane. No experimental materials are used- only a modified incision technique.",[60],"Insufficient Bone Volume Prior to Implant Surgery",[62,63,64,65,66,67,68],"Implant surgery","wound dehiscence","Tooth Collar Technique","flap design","ridge augmentation","bone regeneration","wound closure","NOT_YET_RECRUITING","2026-08-05",{"date":72,"type":37},"2026-08-07",{"date":74,"type":22},"2026-09",{"date":76,"type":22},"2028-08",{"name":43,"class":44},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},"100650508","quality-of-life-psychosocial-burden-and-structural-functional-status-in-adults-with-spinal-deformity-100650508","NCT07749534","Quality of Life, Psychosocial Burden, and Structural-functional Status in Adults With Spinal Deformity.","ASD-QoL","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Age at inclusion 18 years or older.\n3. Diagnosed with Adult spinal deformity\n4. Planned routine management through one of the following pathways:\n\n   1. Conservative\u002Fnon-operative management;\n   2. Primary ASD surgery;\n   3. Revision ASD surgery.\n5. Ability to complete the Dutch-language questionnaire package.\n\nExclusion Criteria:\n\n1. No valid informed consent.\n2. Missing baseline structural imaging required for endpoint determination. We allow images to be older than 2 years if no new radiographs are obtained, in accordance with the ALARA principle.\n3. Inability to complete the Dutch-language questionnaire package.\n4. Known cognitive impairment, severe psychiatric condition, or other condition that, in the Investigator's judgement, precludes valid informed consent or reliable completion of study assessments.\n5. Primary spinal condition other than adult spinal deformity that is expected to invalidate endpoint assessment, including acute traumatic, infectious, tumour-related, or inflammatory spinal pathology as the main reason for presentation.",{"count":86,"type":22},320,[25],"This study examines which factors influence quality of life in adults with a spinal deformity. It looks at imaging findings together with pain, daily functioning, psychosocial factors, and frailty to support more person-centred care.\n\nA total of 320 adults will participate in three groups: conservative treatment, first corrective surgery, or reoperation. All care follows standard practice; no experimental treatments are added. Participants complete questionnaires, and routine FASD tests and existing EOS\u002FX-ray images may be used.\n\nFollow-up lasts up to 2 years, with scheduled assessments depending on whether treatment is surgical or conservative.",[90,91,92],"ASD","Scoliosis Idiopathic Adolescent","Scoliosis Idiopathic Adolescent Treatment",[94,95,96,97],"scoliosis","asd","QOL","quality of life","2026-08-04",{"date":100,"type":37},"2026-08-06",{"date":102,"type":22},"2026-08",{"date":104,"type":22},"2029-07",{"name":43,"class":44},1,{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":23,"phases":117,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":129,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100580027","phase-2-lifestyle-intervention-to-enhance-efficacy-of-neoadjuvant-therapy-in-patients-with-triple-negative-breast-cancer-100580027","NCT06831955","LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","The LESLIE Trial: LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Systemic Therapy in Patients With Triple Negative Breast Cancer","LESLIE","Inclusion Criteria:\n\n* The patient has a biopsy-confirmed diagnosis of stage II-III TNBC\n\n  1. Patients with tumor stage T1cN1-2, T2N0-N2, T3N0-N2, T4N0-N2\n  2. ER and PR negative is defined as an absent or minimal (≤10%) expression of oestrogen and progesterone receptors and absence of HER2 protein over-expression per ASCO\u002FCAP-guidelines\n  3. All histological subtypes are eligible, including but not limited to invasive breast cancer of no special type (NST) , invasive lobular carcinoma (ILC) etc\n* WHO\u002FECOG performance status of grade 0-1\n* The participant is able to perform a CPET test (cardiopulmonary exercise testing)\n* Body mass index ≥ 18.5 kg\u002Fm²\n* Pregnant or breastfeeding women\n* Presence of adequate bone marrow and organ function\n* HbA1c \\\u003C10%\n\nExclusion Criteria:\n\n* had a treatment with any of the following:\n\n  1. any other chemotherapy, immunotherapy or anticancer agents within 5 years of the first dose of study treatment\n  2. injectable hypoglycemics 2. have not have recovered adequately from the toxicity and\u002For complications from a surgical intervention prior to starting therapy\n* prior systemic treatment for breast cancer or other malignancies within 5 years of treatment enrollment, except for adequately treated basal cell or squamous skin cancer or in situ cervical cancer. Other malignancies diagnosed more than 5 years before the diagnosis of breast cancer must have been radically treated without evidence of relapse at the moment of patient enrollment in the trial.\n* has a history of an additional malignancy that is progressing or that has required active treatment in the 5 years prior to breast cancer diagnosis. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n* Prior treatment with anthracyclines\n* Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137)\n* Has any disorder, which in the Investigator's opinion might jeopardize the participant's safety or compliance with the protocol\n* Has, as judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV). Screening for chronic conditions is not required\n* Active autoimmune diseases requiring systemic treatments\n* Patients with type 1 diabetes mellitus\n* History of alcohol use disorder (DSM-5)\n* History of eating disorder (DSM-5)",{"count":116,"type":22},356,[118],"PHASE2","LESLIE is a multicentric randomized controlled trial in patients with triple negative breast cancer receiving neoadjuvant chemo\u002Fimmunotherapy (NAT). This trial investigates the hypothesis that adding a cyclic fasting-mimicking diet combined with exercise during the NAT improves the NAT's therapeutic efficacy, treatment tolerability and compliance, as well as improve quality of life.",[121],"Triple Negative Breast Cancer (TNBC), Early Setting",[123,124,125,126,127,128],"Triple Negative Breast Cancer","Lifestyle Intervention","Neoadjuvant treatment","Fasting-Mimicking Diet","Exercise therapy","Pathological Complete Response",{"date":72,"type":37},{"date":131,"type":37},"2026-02-01",{"date":133,"type":22},"2031-09-01",{"name":43,"class":44},10,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":54,"minAge":143,"maxAge":19,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100649920","body-image-identity-development-and-social-media-use-among-youth-with-visual-impairment-a-single-case-intervention-study-100649920","NCT07741500","Body Image, Identity Development, and Social Media Use Among Youth With Visual Impairment: A Single Case Intervention Study","VIPPSTAR_G3KUL","Inclusion Criteria:\n\n* Children with (C)VI\n* Participants should be aged between 10-18 years old\n* Participants should be able to understand Dutch sufficiently\n* Participants should be cognitively able to comprehend the questions\n* A completed ICF by the parent if the participant is under 18 years of age and a completed assent form by the participant\n\nExclusion Criteria:\n\n* Intellectual disability of such severity that they are unable to respond to the questions (as indicated by parents)\n* Non-Dutch Speaking (as indicated by parents)","10 Years",{"count":145,"type":22},15,[25],"1\\. Introduction\n\nThis 3-week single case intervention study is funded by the Horizon Europe Research Program and is part of the VIPPSTAR project (Project 101156763 - VIPPSTAR \"Visually Impaired children and adolescents: bridging the gap with Personalized Prevention Strategies, Tools, Approaches, and Resources). Within this project, the Belgian consortium will focus on the development of body image in relation to the social media use of children (10-11 years old) and adolescents (12-18 years old) with visual impairment (VI). This intervention study builds upon the insights done in earlier studies within the project, a focus group study and daily diary study. In the intervention study, children and adolescents with visual impairment will complete digital body image exercises through the first version of VIPPSTAR app. It is important to note that the data collection for this particular study will be limited to Flanders, Belgium, and will not extend to the other countries involved in the VIPPSTAR project. Furthermore, the ethical approval obtained for this study is specifically for collecting data from Flemish participants only, ensuring compliance with local ethical guidelines and regulations.",[149,150,151],"Visual Impairment","Cerebral Visual Impairment","Visual Impairments",[153,154,155],"Visual impairment","Cerebral visual impairment","Digital intervention","2026-07-29",{"date":158,"type":37},"2026-08-03",{"date":160,"type":22},"2027-05-01",{"date":162,"type":22},"2028-12-31",{"name":43,"class":44},2,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":54,"minAge":172,"maxAge":173,"enrollmentInfo":174,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":177,"conditions":178,"keywords":180,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":195},"100648911","securing-access-to-innovative-molecules-in-oncology-and-hematology-for-children-adolescents-and-young-adults-100648911","NCT07727694","Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults","(SACHA)","Inclusion Criteria:\n\n* Age ≤ 25 at the time of inclusion in the study\n* Patient with a pediatric malignancy (solid tumor or leukemia), or other related condition\n* Patient not currently enrolled on any other trial for ongoing therapeutic purposes\n* Patient treated with compassionate use of experimental drugs or off-label administration use of anti-cancer medicines first approved in adults after 2007 in Europe\n* Patient discussed in a Pediatric multidisciplinary tumor boards (MDTB) to validate the inclusion in the SACHA study\n* Consent to participate by the patient or his\u002Fher legal representatives in the study if required by ta particular national jurisdiction\n\nExclusion Criteria:\n\n* Patient receiving the drug within a clinical trial.\n* Oral refusal to participate to the study, by the patient or his\u002Fher parents\u002Flegal representatives.","0 Years","25 Years",{"count":175,"type":22},1600,"OBSERVATIONAL","It involves collecting safety and efficacy data, under the actual conditions of use of off label and compassionate use medicines in children and adolescents approved in humans before 2007, using a validated tool (Ennov EDC) and relying on the network recognised pediatric hemato-oncology centers in Belgium and responsible for the organization of Pediatric National tumor boards which discuss each case of relapse in order to define the best therapeutic options.",[179],"Pediatric Cancer",[181,182,183,184,185,186],"observational","data collection","childhood cancer","pediatric cancer","off label medication","CU medication","2026-07-22",{"date":189,"type":37},"2026-07-27",{"date":191,"type":22},"2026-07",{"date":193,"type":22},"2030-12-31",{"name":43,"class":44},6,{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":203,"sex":54,"minAge":19,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":213,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":106},"100647913","short-chain-fatty-acids-in-lypopolysaccharide-induced-inflammation-and-executive-function-100647913","NCT07713641","Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function","Investigating the Role of Short-Chain Fatty Acids in Endotoxemia-Induced Inflammation and Core Executive Functioning: A Randomized, Triple-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Voluntary written informed consent obtained prior to any study procedure\n* Healthy, with no gastrointestinal or psychological complaints\n* Age 18-45 years\n* BMI 18.5-27 kg\u002Fm2\n* Proficiency in English and\u002For Dutch\n\nExclusion Criteria:\n\n* History of previous or current neurological disorder (e.g., epilepsy, multiple sclerosis, migraine with aura)\n* History of previous or current psychiatric disorder (e.g., depression, anxiety disorders, bipolar disorder, schizophrenia)\n* History of previous or current gastrointestinal disorder (e.g., Crohn's disease, ulcerative colitis, irritable bowel syndrome)\n* History of previous or current endocrine disorder (e.g., diabetes, thyroid disorders, polycystic ovary syndrome)\n* History of immune system disorder, including inflammatory, autoimmune, or severe allergic conditions (e.g., rheumatoid arthritis, lupus, celiac disease, or severe allergies such as anaphylaxis)\n* History of neuropsychiatric disorder (e.g., ADHD, autism spectrum disorder, learning disorder, Tourette's syndrome)\n* History of major head trauma (e.g., concussion with loss of consciousness or long-term symptoms)\n* History of severe infection (e.g., sepsis, pneumonia requiring hospitalization, meningitis, endocarditis, or other systemic infection requiring hospitalization, intravenous antibiotics, or intensive care)\n* One or more diagnoses based on the Mini International Neuropsychiatric Interview (MINI)\n* One or more diagnoses based on ROME-IV criteria for gastrointestinal disorders\n* Any disorder that, in the investigator's opinion, might jeopardise the participant's safety or compliance with the protocol\n* Any prior or concomitant treatment that might jeopardise the participant's safety or compromise the integrity of the study\n* Participation in an interventional trial with an investigational medicinal product (IMP) or device\n* Current or recent (past month) prescribed medication use, with particular attention to cardiovascular drugs, steroids, NSAIDs, and centrally-acting drugs (excluding isolated over-the-counter use such as ibuprofen or paracetamol, and hormonal contraceptives in women)\n* Use of psychotropic medication within the past year (e.g., antidepressants, anxiolytics, antipsychotics)\n* Use of antibiotics within three months preceding the study\n* Use of pre- or probiotics within one month preceding the study\n* Current or recent (past month) infection (e.g., common cold, influenza, COVID-19)\n* Recent (past month) vaccination\n* Pregnant or lactating women\n* Previous or current substance or alcohol dependence or abuse (\\>2 units\u002Fday or \\>14 units\u002Fweek)\n* Smoking\n* Night-shift work\n* Adherence to special diets (e.g., vegan, vegetarian, weight-loss, lactose-free, gluten-free)\n* Previous experience with or knowledge of any of the cognitive tasks used in the study (questionnaires excluded)\n* C-reactive protein higher than 0.5mg\u002FdL on the day of the injection.\n* Colour vision deficiency or colour-blindness",true,"45 Years",{"count":206,"type":22},56,[25],"Short-chain fatty acids (SCFAs) are substances produced by gut bacteria when they ferment dietary fiber. They can act as signals between the gut and the brain and may help regulate the body's immune and stress responses. Earlier work has shown that delivering SCFAs to the colon can lower the stress hormone response to a mental stress task in healthy people, and laboratory studies suggest SCFAs can reduce inflammation. However, it is not yet known whether SCFAs can reduce inflammation in humans, or whether doing so protects mental performance.\n\nThis study uses a controlled, acute, and short-lasting challenge. Healthy adults receive a single, low dose of a bacterial substance called lipopolysaccharide (LPS) through a vein. LPS briefly activates the immune system and causes mild, flu-like symptoms (such as fatigue, headache, and feeling unwell) that pass on their own within a few hours. It does not cause a real infection.\n\nParticipants are randomly assigned to take either SCFA capsules or inactive placebo capsules on the morning of the test day, before the LPS challenge. Neither the participants, the researchers running the visit, nor the researchers analyzing the results know who received which capsules until the study is complete (triple-blind).\n\nThe main goal of the study is to test whether SCFAs, compared with placebo, reduce the inflammatory response to LPS, measured by markers of inflammation in the blood. The study also examines whether SCFAs reduce the associated sickness symptoms and whether they protect performance on tasks that measure core executive functions: the ability to keep relevant information in mind (working memory), the ability to hold back automatic responses or thoughts (inhibition), and the ability to switch flexibly between tasks or rules (cognitive flexibility). Blood, saliva, and stool samples are collected to measure inflammation markers, SCFA levels, stress hormones, and gut bacteria.\n\nParticipants attend a screening visit, a test day with monitoring for several hours, and a short follow-up visit the next day.",[210,211,212],"Endotoxemia","Inflammation","Executive Function (Cognition)",[214,215,216,217,218,219,220,221,222,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239],"scfa","short-chain fatty acids","butyrate","proprionate","acetate","lypopolysaccharide","lps","endotoxemia","lps challenge","experimental","inflammation","experimental inflammation","experimental endotoxemia","systemic inflammation","gut-brain axis","microbiota","microbiota-gut-brain axis","executive function","working memory","inhibition","cognitive inhibition","response inhibition","cognitive flexibility","task switching","healthy volunteers","sickness behaviour","2026-07-14",{"date":242,"type":37},"2026-07-20",{"date":244,"type":37},"2025-10-24",{"date":246,"type":22},"2027-03-30",{"name":43,"class":44},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":23,"phases":258,"briefSummary":259,"conditions":260,"keywords":262,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":268,"leadSponsor":270,"locationsCount":106},"100630738","evaluation-of-the-5c-medic-knee-system-100630738","NCT07491575","Evaluation of the 5C® MEDic Knee System","Evaluation of the Midterm Results of the 5C® MEDic Knee System","5C Knee","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. The patient will be operated at the Leuven University Hospital (primary or revision surgery).\n4. The patient will receive the 5C® MEDic Knee System (manufactured by implantcast GmbH).\n5. The implantation will be performed according to the medical indications listed in the product specific Instruction for Use (IFU):\n\n   1. Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis,\n   2. Post-traumatic osteoarthritis\n   3. Treatment of fractures that are unmanageable using other surgical techniques\n   4. Rheumatoid arthritis\n   5. Revision arthroplasty (revision prosthesis)\n6. The patient is willing and able to follow all study specific procedures and to attend the follow-up visits at the study site\n7. The patient agrees to be contacted by telephone or by mail.\n\nExclusion Criteria:\n\n1. The patient is \\\u003C18 years of age, or unable to understand and sign a written informed consent form or legally incompetent or limited in his legal capacity.\n2. Patient has history of malignancy within the past 5 years before screening.\n3. Patients with Adipositas permagna (BMI ≥40 kg\u002Fm²).\n4. Has a current infection as well as infections close (in the opinion of the investigator) to the knee joint within the last 3 years.\n5. Known allergy to any of the implant materials.\n6. Female who is pregnant or intends to become pregnant during screening and at the moment of operation\n7. Not a suitable candidate for enrollment or unlikely to comply with the requirements of this study, as assessed by the Investigator.\n8. Current alcohol and\u002For drug abuse or other addictions that might impair the patient's capacity to estimate the nature and the scope of the study.\n9. Bilateral Total Knee Arthroplasty in a period of \\\u003C 3 months.\n10. Physiological or anatomical conditions, which preclude or are not expected to maintain adequate bony support of the implant or do not allow the implantation of a sufficiently large prosthesis, in the opinion of the investigator.\n11. Bone tumors in the implant fixation area.\n12. Has an untreated vascular diseases which limit blood supply to the affected limb, in the opinion of the investigator\n13. Has a metabolic disorders that may impair bone formation.\n14. In case of insufficient quantity and quality of bone stock, an alternative prosthetic treatment allowing for sufficient bony fixation should be considered.\n15. Has severe axis deviation in treated knee under study and\u002For non-treated knee.\n16. Ligament instability in treated knee under study.\n17. Participation in an interventional trial with an investigational medicinal product (IMP) or device within the last four weeks before Screening.\n18. Any other clinical history finding that, in the judgment of the investigator, would pose a potential hazard for performing a knee surgery",{"count":257,"type":22},100,[25],"This prospective study wants to demonstrate the safety and clinical performance of the 5C® MEDic Knee System following total knee arthroplasty. Additionally, all observed product-related complications are documented during the course of the follow-up study. These observations help to re-assess current (known) risks and identify new ones. The data obtained during this study is part of the post market surveillance.",[261],"Knee Degenerative Disease",[263],"5C® MEDic","2026-07-09",{"date":266,"type":37},"2026-07-10",{"date":191,"type":22},{"date":269,"type":22},"2035-04",{"name":43,"class":44},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":23,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":106},"100629960","altered-joint-mechanics-and-biological-response-in-osteoarthritic-knees-100629960","NCT07481461","Altered Joint Mechanics and Biological Response in Osteoarthritic Knees.","Altered Joint Mechanics and Biological Response in Osteoarthritic Knees. A Study in Patients Undergoing Corrective Treatment for Knee Misalignment.","AMB-OK","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* Chronic symptoms of (early) knee OA.\n* Misalignment of the lower limb and scheduled for HTO surgery (regardless of the HTO technique used (lateral or medial, closing or opening wedge)) or brace treatment.\n* Follow-up at UZ Leuven.\n\nExclusion Criteria:\n\n* Acute OA symptoms onset (previous knee injury)\n* Pregnant women\n* MRI checklist incomplete or failed\n* BMI \\> 30\n* Impaired vision or neurological condition that affect coordination and balance\n* Age \\\u003C18 (no minors will be included in the study)",{"count":56,"type":22},[25],"Osteoarthritis (OA) stands out as the most prevalent joint disease. It manifests as a progressive degradation of articular cartilage, new bone growth and often synovial tissue proliferation, resulting in pain and compromised joint functionality, ultimately leading to disability. Misalignment of the lower limb (varus or valgus knees) are recognised as a risk factor for osteoarthritis onset and progression. High tibial osteotomy (HTO) is a surgical technique that allows to shift the load from the affected area to other areas with intact cartilage. Similarly to HTO, braces realign the lower limb, without the need for surgical intervention. These corrective treatments are recommended for the youngest group of patients as it allows them to stay active, as opposed to Total Knee Replacement (TKR). Until today, the effects of braces and HTO on the subchondral bone microstructure and cartilage are not well understood. Investigating these aspects to better understand treatment failures is becoming more and more crucial because global prevalence of knee OA is expected to increase with the ageing of populations.",[283],"Knee Osteoarthritis (OA)",{"date":266,"type":37},{"date":286,"type":37},"2026-05-12",{"date":288,"type":22},"2030-04",{"name":43,"class":44},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":306,"leadSponsor":308,"locationsCount":106},"100629959","long-term-aseptic-revision--advanced-hip-arthroplasty-database-100629959","NCT07481448","Long-term Aseptic Revision & Advanced Hip Arthroplasty Database","Long-term Follow-up of Patients Undergoing Aseptic Revision Hip Arthroplasty or Complex Primary Hip Arthroplasty Treated at University Hospitals Leuven","LARA","Inclusion Criteria:\n\n* Patients undergoing a hip replacement for the following indications:\n\n  1. THA with hardware removal\n  2. THA for hip dysplasia\n  3. THA with femoral deformity or prior corrective surgery\n  4. THA after LCPD, SCFE or septic arthritis\n  5. THA in metabolic disease\n  6. THA in hyperlaxity (e.g. Ehlers-Danlos syndrome, Down syndrome)\n  7. THA with complex bony anatomy\n  8. THA in patients aged 25 years or younger\n  9. Other indications for which the treating surgeon expects increased surgical difficulty or increased risk of postoperative complications\n\n     Exclusion Criteria:\n* Patients unable to provide written informed consent\n* Patients who prefer treatment outside of University Hospitals Leuven\n* Patients with proven PJI according to the 2021 EBJIS criteria\n* Patients undergoing standard, non-complex, hip replacement as judged by the treating physician.",{"count":299,"type":22},200,"Total hip arthroplasty (THA) volumes continue to rise each year as the population ages and indications broaden. Increasingly, younger patients require hip replacement for conditions beyond primary osteoarthritis or fractures. As a result, the number of revision procedures is growing and is expected to increase further.\n\nProspective data collection within this population will enable us to address key uncertainties, particularly around optimal implant selection for complex primary and revision cases.\n\nIn addition, establishing a structured prospective database will allow for systematic internal auditing for quality assurance. Even simple metrics - such as verifying whether every patient received a complete diagnostic infection workup before revision surgery - could immediately enhance service quality and inform improvements to clinical pathways.",[302],"Hip Arthropathy Associated With Other Conditions",{"date":304,"type":37},"2026-07-13",{"date":191,"type":22},{"date":307,"type":22},"2037-03",{"name":43,"class":44},{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":203,"sex":54,"minAge":19,"maxAge":317,"enrollmentInfo":318,"targetDuration":4,"studyType":23,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":106},"100536129","biomechanical-and-morphological-characterization-of-pttd-100536129","NCT06260813","Biomechanical and Morphological Characterization of PTTD","Biomechanical and Morphological Characterization of the Foot in Patients With Posterior Tibial Tendon Dysfunction.","PTTD","Inclusion criteria:\n\n* Patient groups:\n\n  * Posterior tibial tendon dysfunction (all clinical stages)\n  * Age 18-675 year\n  * ICF obtained\n* Control group:\n\n  * No pain complaints\n  * No pes plano valgus, PTTD or pes cavo varus or other foot and ankle pathology\n  * Age 18-75 year\n  * ICF obtained\n\nExclusion criteria patient and control groups:\n\n* Being younger than 18 years\n* Inability to walk without mobility aids\n* Inability to walk \\\u003C 100 meter\n* Difference in leg length \\> 3cm\n* Subjects with BMI\\>30 kg\u002Fm², due to less accurate gait analysis by absence of anatomical landmarks\n* Subjects unable to perform a gait analysis\n* Any medical condition possibly affecting normal gait.\n* Pregnancy: at the start or during the study","75 Years",{"count":257,"type":22},[25],"Posterior tibial tendon dysfunction (PTTD) is a progressive condition of the tendon of the tibialis posterior muscle with symptoms of tendinopathy or even rupture. Functionally, it is associated with the inability to lock the mid foot and thus manifests itself as a main contributor to adult acquired flatfoot deformity.\n\nConcerning treatment, clinical decision making is currently based on a classification integrating various parameters as pain, flexibility of the foot joints, the condition of the posterior tibial tendon assessed through ultrasound imaging and radiographic assessment of arthritic changes. Surprisingly, this classification does not consider any morphologic characteristics (the shape of a bone or joint) or functional, biomechanical characteristics of the foot and ankle, i.e. based on kinematics (e.g. range of motion) and\u002For kinetics (center of pressure, angular velocity, moment, power absorption and power generation of a joint).\n\nDetailed biomechanical characteristics of the foot and ankle can be reliably collected by instrumented gait analysis wherein a 3D camera system is combined with a force plate and plantar pressure platform. Kinematic studies in the field of PTTD typically considered the foot as a structure consisting of three segments: hind foot, forefoot and hallux. Consequently, the mid foot segment (the Chopart and Lisfranc joints) has been neglected, although it is this segment that is particularly affected in PTTD patients.\n\nThe aim of this research is to overcome the limitations of the current classification system and treatment of PTTD patients, by complementing the current standard-of-care clinical assessment with better insight in the pathologic changes that occur in PTTD patients.",[322],"Posterior Tibial Tendon Dysfunction",{"date":266,"type":37},{"date":325,"type":37},"2022-08-22",{"date":327,"type":22},"2028-08-01",{"name":43,"class":44},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":23,"phases":338,"briefSummary":339,"conditions":340,"keywords":343,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":4},"100645014","phase-2-clinical-study-of-local-and-systemic-biological-impact-of-glp1gip-receptor-agonists-in-patients-with-breast-cancer-the-clara-trial-100645014","NCT07676331","Clinical Study of Local and Systemic Biological Impact of GLP1\u002FGIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial","CLARA","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. Patient is \\>18 years of age\n3. Patient is postmenopausal, as defined per local practice\n4. Tumour size of ≥1 cm\n5. The patient has a biopsy-confirmed diagnosis of GII-III ER+, HER2 - early stage breast cancer scheduled for primary surgery as per standard-of-care\n\n   1. To fulfil the requirement for HR+ disease by local testing on primary disease specimen, tumour must be ER positive defined by immunohistochemistry (IHC) according to American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines for hormone receptor testing.\n   2. To fulfil the requirement of HER2- disease by local testing on primary disease specimen, tumour must be HER2- according to ASCO\u002FCAP guidelines for HER2 testing\n   3. All histological subtypes are eligible, including but not limited to invasive breast cancer of no special type (IBC-NST) , invasive lobular carcinoma (ILC) etc.\n6. Have a BMI of\n\n   1. ≥30 kg\u002Fm2 or\n   2. ≥27 kg\u002Fm2 and previously diagnosed with at least 1 of the following weight-related comorbidities:\n\n   i. Hypertension: treated or with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg ii. Dyslipidaemia: treated or with LDL ≥160 mg\u002FdL (4.1 mmol\u002FL) or triglycerides ≥150 mg\u002FdL (1.7 mmol\u002FL), or HDL iii. Obstructive sleep apnoea iv. Cardiovascular disease, for example, ischemic cardiovascular disease, New York Heart Association Functional Classification Class I-III heart failure\n7. Patient should be able to read\u002Funderstand Dutch, French or English\n8. Willing to commit to the study program and comply with all related protocol procedures\n9. Willing to undergo a new biopsy of the breast lesion in case no formalin-fixed paraffin-embedded (FFPE) block can be made available for the trial.\n\nExclusion Criteria:\n\n1. Have Type 1 or 2 diabetes mellitus, history of ketoacidosis, or hyperosmolar state or coma.\n2. Have at least 1 laboratory value suggestive of diabetes during screening : HbA1c ≥6.5% (≥48 mmol\u002Fmol) or fasting glucose ≥126 mg\u002FdL (≥7.0 mmol\u002FL)\n3. Have a history of BC exceptions are made for:\n\n   1. Contralateral in situ BC without systemic treatment\n   2. Ipsilateral in situ BC without systemic treatment or radiation therapy\n4. Have a history of an additional invasive malignancy that is progressing or that has required active treatment in the 3 years prior to breast cancer diagnosis. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n5. Are receiving or has received within 3 months prior to screening systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled preparations) or have evidence of a significant, active autoimmune that has required (within the last 3 months) or is likely to require, in the opinion of the investigator, concurrent treatment with systemic treatment (such as glucocorticoids (excluding topical, intraocular, intranasal, intra-articular, or inhaled preparations)) during the course of the study.\n\n   Note: Replacement therapy with thyroxine is not a contraindication for inclusion if patient is already on same dose for 3 months\n6. Have a history of any other condition, such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder, that, in the opinion of the investigator, may preclude the participant from following and completing the protocol\n7. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n8. Have a self-reported change in body weight \\>5 kg within 3 months prior to screening\n9. Have a prior surgical treatment for obesity, excluding liposuction or abdominoplasty\n10. Have endoscopic and\u002For device-based therapy for obesity or have had device removal within the last 6 months prior to screening\n11. Have renal impairment measured as eGFR \\\u003C30L\u002Fmin\u002F1.73m2\n12. Have a known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility\n13. Have a history of chronic or acute pancreatitis\n14. Is treated with insulin or other hypoglycaemic drugs\n15. Participation in another interventional Trial with an investigational medicinal product (IMP) or device in the neoadjuvant setting\n16. Have obesity induced by other endocrinologic disorders, for example, Cushing syndrome, or diagnosed monogenetic or syndromic forms of obesity\n17. Has acute or chronic hepatitis, signs and symptoms of any other liver disease other than NAFLD, or any of the following, as determined by the central laboratory during screening:\n\n    1. Alanine aminotransferase (ALT) level \\>3.0x ULN for the reference range\n    2. Alkaline phosphatase (ALP) level \\>2.0x ULN for the reference range, or\n    3. Total bilirubin level \\>1.5x ULN for the reference range (except for cases of known Gilbert's Syndrome) Note: Participants with non-alcoholic fatty liver disease (NAFLD) are eligible to participate in this trial if their ALT level is ≤3.0x ULN for the reference range\n18. Has used systemic hormonal substitution therapy within 2 months before screening\n19. Has used a GLP1\u002F(GIP)\u002F(GC) Receptor Agonist within 2 months of screening\n20. Has used medications (prescribed or over-the-counter) within 2 months prior to screening that promote weight loss.",{"count":337,"type":22},168,[118],"The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1\u002FGIP receptor agonist) affects breast cancer biology, alone and in combination with standard hormone therapy (letrozole).\n\nThe main goal is to determine whether tirzepatide, alone or combined with letrozole, reduces tumor cell growth.",[341,342],"Hormone-receptor-positive Breast Cancer","Early Breast Cancer",[344,345,346,347,348],"GLP-1\u002FGIP receptor agonist","tirzepatide","letrozole","Window-of-opportunity trial","Weight-loss drugs","2026-07-03",{"date":351,"type":37},"2026-07-07",{"date":353,"type":22},"2026-08-01",{"date":355,"type":22},"2028-05-01",{"name":43,"class":44},{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":386},"100483033","phase-3-semaglutide-for-the-treatment-of-glucose-intolerance-in-women-with-prior-gestational-diabetes-100483033","NCT05569772","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT","SERENA","Eligible participants are women aged ≥18 years, with a history of GDM diagnosed according to the 2013 WHO criteria (at 24-32 weeks gestation or \\\u003C24 weeks for early GDM). Participants must have prediabetes diagnosed between 6 weeks and 12 months postpartum according to ADA criteria (FPG 5.6-6.9 mmol\u002FL, 2-hour OGTT glucose 7.8-11.0 mmol\u002FL and\u002For HbA1c 39-46 mmol\u002Fmol \\[5.7-6.4%\\]).\n\nAdditional inclusion criteria include cessation of breastfeeding, no intention to become pregnant within the next year, use of effective contraception and no use of medication affecting glucose metabolism. Written ICF is obtained prior to any study-related procedures.\n\nExclusion criteria include established diabetes, presence of autoantibodies suggestive of type 1 diabetes, normal glucose tolerance, history of pancreatitis, previous bariatric surgery or planned surgery within two years, unable to understand and speak Dutch, French or English and current pregnant or planning to become pregnant within one year after participating in the study.",{"count":366,"type":22},252,[368],"PHASE3","Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.",[371],"Glucose Intolerance After a Recent History of Gestational Diabetes",[373,374,375,376,377,378],"gestational diabetes","glucose intolerance postpartum","prevention","type 2 diabetes","GLP-1 agonist","semaglutide","2026-07-02",{"date":351,"type":37},{"date":382,"type":37},"2023-09-14",{"date":384,"type":22},"2029-12",{"name":43,"class":44},13,{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":393,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":407,"locationsCount":4},"100644786","improving-prognostication-in-colon-cancer-100644786","NCT07673393","Improving Prognostication in Colon Cancer","Improving Prognostication of Localised Colon Cancer by Combining Liquid Biopsy and Histology: a Multicentric, Prospective Study","MARBLE","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed primary colon tumor clinically and\u002For histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.\n4. Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.\n5. WHO (ECOG) performance status ≤ 3 at baseline.\n\nExclusion Criteria:\n\n1. Participant has been diagnosed with metastatic disease (Stage IV)\n2. Participant has been diagnosed with rectal cancer\n3. Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)\n4. Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer\n5. Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.\n6. Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.\n7. Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).",{"count":396,"type":22},400,"The goal of this study is to test better ways to predict if cancer will return after surgery in adults (18+) who have been diagnosed with stage II or III colon cancer.\n\nThe main questions it aims to answer are:\n\n* Can computer programs (Artificial Intelligence) and special blood tests give more accurate information about the risk of cancer returning than the methods doctors use today?\n* Does combining these new tests help doctors better understand which patients really need chemotherapy and which do not?\n\nResearchers will compare the new computer and blood tests to the standard hospital methods used now to see if the new way is more accurate in predicting the cancer's behavior\n\nParticipants will:\n\n* Sign a form saying they agree to take part in the study\n* Have their standard surgery to remove the tumor\n* Give a few extra teaspoons of blood during their regular, scheduled hospital visits\n* Allow researchers to scan and study a small piece of the tumor that was already removed during surgery\n* Continue with their normal hospital check-ups for up to five years so researchers can track their health",[399,400],"Colon Cancer","Colon Adenocarcinoma","2026-06-22",{"date":403,"type":37},"2026-06-29",{"date":74,"type":22},{"date":406,"type":22},"2033-09",{"name":43,"class":44},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":203,"sex":54,"minAge":416,"maxAge":417,"enrollmentInfo":418,"targetDuration":4,"studyType":23,"phases":420,"briefSummary":421,"conditions":422,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":106},"100644106","blood-based-biomarkers-for-alzheimers-disease-at-the-primary-care-level-100644106","NCT07666113","Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.","The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.","ADPriK","Inclusion Criteria:\n\n* Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.\n\nExclusion Criteria:\n\n* Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).\n* Concomitant medications that would interfere with cognitive assessments.\n* A prior diagnosis of AD and related disorders or other neurodegenerative disease.","55 Years","85 Years",{"count":419,"type":22},240,[25],"The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217\u002FAβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.\n\nParticipants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.",[423],"Alzheimer's Disease (AD)","2026-06-17",{"date":426,"type":37},"2026-06-24",{"date":428,"type":37},"2026-05-26",{"date":430,"type":22},"2038-04",{"name":43,"class":44},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":442,"briefSummary":443,"conditions":444,"keywords":450,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":456,"lastUpdatePostDateStruct":457,"startDateStruct":459,"completionDateStruct":461,"leadSponsor":463,"locationsCount":106},"100633236","the-application-of-infrared-thermography-in-the-prediction-of-skin-healing-in-surgery-100633236","NCT07524062","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery THERMS: THermography for Evaluation of Recovery and Monitoring of Surgical Wounds","THERMS","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Adult subjects (\\>18 years of age) at time of enrolment\n3. Patients undergoing a surgical excision under local anesthesia\n4. Indications of the excisions were skin lesions suspected to be malignant, skin lesions confirmed to be malignant via prior biopsy\n\nExclusion Criteria:\n\n1. Patient has history of pre-existing diabetes type I and II\n2. Patients with pre-existing chronic wound problems\n3. Patients with renal dysfunction,\n4. Patients with venous insufficiency confirmed via radiographic imaging\n5. Patients who received radiotherapy in the affected area in the past\n6. Patients with chronic steroid use in the past (\\> 3 months) or a immunosuppressant medication history\n7. Female who is pregnant",{"count":441,"type":22},120,[25],"This study investigates whether infrared thermography, a harmless and non-invasive thermal camera technique, can help monitor how surgical wounds heal after skin surgery. The goal is to detect wound problems earlier, such as infection or delayed healing, and to support doctors in making timely clinical decisions.",[445,446,447,448,449],"Wound Healing","Surgical Wound Infection","Postoperative Complications","Skin Neoplasms","Skin Transplantation",[451,452,453,454,455],"Infrared thermography","Surgical wound healing","Dermatosurgery","Thermal imaging","Wound complications","2026-06-16",{"date":458,"type":37},"2026-06-18",{"date":460,"type":37},"2026-06-15",{"date":462,"type":22},"2028-10",{"name":43,"class":44},{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":176,"phases":4,"briefSummary":473,"conditions":474,"keywords":477,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":106},"100613404","prospective-collection-of-clinical-data-and-human-body-material-hbm-of-cutaneous-melanoma-non-melanoma-patients-and-healthy-controls-biobank-huidkanker-100613404","NCT07266142","Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Adult subjects (\\>18 years of age) at time of enrolment.\n* Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls.\n* Adult subjects able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects unable or not willing to provide informed consent.\n* Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.",{"count":472,"type":22},7500,"The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.\n\nThe main questions it aims to answer are:\n\n* To create a biobank with samples of human body material (HBM): blood (serum\u002Fplasma\u002FDNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls.\n* To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols).\n\nIf there is a comparison group: Not applicable (umbrella protocol for collection only).\n\nParticipants will:\n\n* Share demographics, medical and surgical history, risk factors.\n* Complete Cancer Worry Scale questionnaire.\n* Provide biological samples:\n\n  * Blood samples (serum, plasma, DNA).\n  * Tissue samples (residual tissue or additional biopsy if consented).",[475,476],"Skin Cancer, Non-Melanoma","Skin Cancer Melanoma",[478,479,480],"Prospective Collection","Skin Cancer","Human Body Material","2026-06-10",{"date":483,"type":37},"2026-06-12",{"date":485,"type":37},"2025-11-17",{"date":487,"type":22},"2051-01",{"name":43,"class":44},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":12,"sex":54,"minAge":4,"maxAge":4,"enrollmentInfo":496,"targetDuration":498,"studyType":176,"phases":4,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":106},"100643071","validation-of-sds-edta-treated-chromatography-paper-strips-for-mpox-sampling-and-transport-in-drc-100643071","NCT07634081","Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC","Use of SDS\u002FEDTA-Treated Chromatography Strips for Sampling, Transportation and Laboratory Confirmation of Mpox Virus Infection","Inclusion Criteria:\n\n* Patients presenting with clinical signs compatible with mpox infection according to national case definition.\n* Written informed consent obtained.\n* Presence of at least two skin lesions in a similar stage of evolution suitable for paired sampling.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Presence of only one suitable lesion for sampling.\n* Lesions at markedly different stages of evolution.\n* Inability to safely obtain paired samples.",{"count":497,"type":22},150,"1 Day","The objective of this prospective paired diagnostic comparison study is to evaluate the diagnostic yield and field applicability of SDS-EDTA-treated chromatography paper strips for the collection, transport, and laboratory detection of mpox virus compared with the routine swab-based sampling method under field conditions in the Democratic Republic of the Congo (DRC).\n\nThe study is conducted among patients with suspected mpox infection presenting to healthcare facilities in South Kivu, DRC. For each participant, paired samples are collected simultaneously using the standard swab method and the SDS-EDTA strip method. Samples are analyzed using locally available molecular diagnostic platforms.",[501],"Mpox","2026-06-09",{"date":504,"type":37},"2026-06-11",{"date":506,"type":37},"2026-05-01",{"date":508,"type":22},"2026-07-31",{"name":43,"class":44},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":514,"acronym":515,"eligibilityCriteria":516,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":517,"targetDuration":519,"studyType":176,"phases":4,"briefSummary":520,"conditions":521,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":106},"100643504","cardiac-surgery-the-incidence-and-impact-of-chronic-postoperative-pain-a-survey-100643504","NCT07640646","Cardiac Surgery, the Incidence and Impact of Chronic postOperative Pain: a Survey","Cardiac COPS","Inclusion Criteria:\n\n1. Adults, aged ≥ 18 years of age, who underwent cardiac surgery (valvular, coronary bypass, other intracardiac or aortic surgery) during the 1 year recruitment period\n2. Able to provide informed consent\n3. Able to respond by telephone\n\nExclusion Criteria:\n\n1. Deceased\n2. Refusal\n3. Chronic pain in the surgical region",{"count":518,"type":22},1000,"1 Year","This survey study aims to investigate the incidence of Chronic post surgical pain (CPSP) in cardiac surgery patients treated at UZ Leuven. The primary hypothesis is that the incidence of CPSP at 3 months postoperatively is lower than 33%, which is the rate commonly reported in the literature. Secondary objectives include comparing CPSP incidence based on the type of surgical incision, as well as comparing incidences between type of surgery. Finally, the study will assess pain intensity, interference with daily activities, and quality of life of 3 months and when required also at 1 years postoperatively.",[522,523],"Chronic Postoperative Pain","Cardiac Surgery","2026-06-05",{"date":504,"type":37},{"date":527,"type":37},"2026-06-01",{"date":529,"type":22},"2028-05-31",{"name":43,"class":44},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":23,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":548,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":554},"100539939","continuous-glucose-monitoring-for-women-with-gestational-diabetes-100539939","NCT06310356","Continuous Glucose Monitoring for Women With Gestational Diabetes","Continuous Glucose Monitoring for Women With Gestational Diabetes: a Randomized Controlled Trial","CORDELIA","Inclusion Criteria:\n\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Singleton pregnancy\n* Diagnosed with gestational diabetes before 29.6 weeks of pregnancy\n* Needs to be able to understand and speak Dutch, French or English.\n* Have email access\n\nExclusion Criteria:\n\n* Patient has a history of type 2 or type 1 diabetes, or presence of auto-immune antibodies for type 1 diabetes\n* A physical or psychological disease likely to interfere with the conduct of the study (based on the evaluation by the treating physician).\n* Use of medication with significant impact on glycemia (such as high dose glucocorticoids and diabetes medication such as metformin)\n* Participation in an interventional Trial with an investigational medicinal product or device\n* Multiple pregnancy\n* History of bariatric surgery\n* Known allergy to the adhesives used with the continuous glucose monitoring",{"count":540,"type":22},386,[25],"There are a few ongoing large randomized controlled trials (RCT's) on continuous glucose monitoring (CGM) in women with gestational diabetes (GDM) powered for pregnancy outcomes. However, none of these studies included women diagnosed with early GDM. The CORDELIA trial is a Belgian-Australian open-label multi-centric RCT with 16 centers in women with GDM (including both early and late GDM). Women will be randomized 1\u002F1 to either treatment with CGM (intervention group, Freestyle Libre 3 +) or continue with self-monitoring of blood glucose (SMBG) with glucometer in line with normal routine (control arm). The study ends at the postpartum oral glucose tolerance test (OGTT 6-24 weeks postpartum) to screen for glucose intolerance.",[544],"Gestational Diabetes",[373,546,547],"continuous glucose monitoring","early gestational diabetes",{"date":502,"type":37},{"date":550,"type":37},"2024-11-18",{"date":552,"type":22},"2027-08",{"name":43,"class":44},16,{"id":556,"slug":557,"hasResults":12,"nctId":558,"briefTitle":559,"officialTitle":560,"acronym":561,"eligibilityCriteria":562,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":563,"targetDuration":4,"studyType":23,"phases":565,"briefSummary":566,"conditions":567,"keywords":569,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":576,"completionDateStruct":578,"leadSponsor":580,"locationsCount":164},"100613741","accelerated-pacing-and-cardiac-filling-pressures-during-exercise-in-patients-with-heart-failure-with-preserved-ejection-fraction-100613741","NCT07270536","Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction","The Impact of Accelerated Pacing and AV-delay Regulation on the Pulmonary Capillary Wedge Pressure During Exercise in Patients With HFpEF","APAVE","Participants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. Heart failure with preserved ejection fraction, defined as one of the below criteria:\n\n   1. EF \\>= 45% and HFA-PEFF score \\>= 5 (Heart Failure Association-Pre-test assessment, Echocardiography and natriuretic peptide, Functional testing, Final etiology; heart failure association of the European Society of Cardiology and the Heart Failure Association (34))\n   2. EF \\>= 45% and H2FPEF score \\>= 6 (Heavy, Hypertensive, Atrial fibrillation, Pulmonary hypertension, Elder, Filling pressure; Mayo Clinic group (35)))\n   3. EF \\>= 45% and\n\n   i. History of heart failure hospitalization after pacemaker implantation or ii.On loop-diuretics at time of inclusion\n4. Having a DDD-pacemaker with LBB area pacing, implanted at least 12 weeks before iCPET\n5. \\>=6 weeks on optimal HFpEF therapy (MRA and SGLT2i) at time of iCPET, unless contraindicated or not tolerated\n6. Sinus rhythm at time of screening and iCPET\n\nParticipants eligible for this Study must not meet any of the following criteria:\n\n1. Participant has a history of:\n\n   1. Evidence of significant pulmonary comorbidity based on abnormal pulmonary function tests (FEV1 \\\u003C60%) or aberrant lung parenchyma more than mild on radiological imaging\n   2. Severe\u002Fsymptomatic valvular diseases\n   3. Severe pulmonary hypertension (PASP \\> 55mmHg estimated by Doppler Echo)\n   4. Unstable arrhythmias (VT, VF)\n   5. Recurrent syncopes after pacemaker implantation\n   6. Permanent atrial fibrillation\n   7. Amyloid cardiomyopathy\n2. Physical inability to perform exercise\n3. More than 1 hospitalization for heart failure in the last year\n4. Resting heart rate\\> 100bpm\n5. At time of iCPET or inclusion: decompensated heart failure, unstable coronary syndrome\n6. Contraindication to central venous access\n\n   1. Severe coagulopathy (e.g., spontaneous INR \\> 2, thrombocytopenia \\\u003C 50,000\u002FµL)\n   2. Local infection or skin infection at the insertion site\n   3. Thrombosis or anatomical abnormalities of the right jugular vein\n   4. Pneumothorax or contralateral lung pathology\n   5. Inability to properly position the patient\n7. Contraindication to arterial access\n\n   1. Thrombosis or occlusion of the target artery\n   2. Raynaud's phenomenon or other vasospastic disorders\n   3. Active infection at the intended insertion site\n   4. Severe coagulopathy (e.g., spontaneous INR \\> 2, thrombocytopenia \\\u003C 50,000\u002FµL)\n   5. Insufficient collateral circulation (e.g., inadequate perfusion in an Allen test)\n8. Contraindications to CPET\n\n   1. ECG signifying myocardial injury\n   2. ECG signifying current or potentially lethal arrhythmias\n   3. Systemic hypotension (e.g. systolic blood pressure \\\u003C 90 mmHg)\n   4. Extreme hypertension (e.g. systolic blood pressure \\> 220 mmHg)\n   5. Syncope, presyncope, or lightheadedness\n   6. SaO2 \\\u003C 88%\n   7. Severely elevated PCWP (\\> 40 mmHg) during exercise",{"count":564,"type":22},20,[25],"What is HFpEF? In heart failure with preserved ejection fraction (HFpEF), the heart pumps well but struggles to relax and fill with blood between beats. This raises the pressure inside the heart, especially during physical activity, causing symptoms like shortness of breath and fatigue - even with light activities like walking or climbing stairs.\n\nWhat is this study about? Recent research suggests that a higher heart rate may help lower this elevated pressure. Many HFpEF patients already have a pacemaker. This study investigates whether simply increasing the pacemaker rate during light exercise can reduce the pressure in the heart.\n\nHow does the study work? We wille measure heart pressures in 20 patients in rest and while cycling using a heart catheter and monitor their breathing. Throughout these measurements, we will gradually increase the pacemaker rate step by step.\n\nWhy does this matter? If a higher pacemaker rate successfully lowers heart pressure, this could offer a simple, drug-free way to improve daily functioning and comfort for thousands of patients with HFpEF, justifying further long-term studies to evaluate effects beyond the immediate changes in heart pressures.",[568],"HFpEF",[570,571,572,573],"Heart Failure with Preserved Ejection Fraction","Accelerated pacing","Chronotropic response","Hemodynamics","2026-06-02",{"date":524,"type":37},{"date":577,"type":37},"2025-12-10",{"date":579,"type":22},"2027-03-01",{"name":43,"class":44},{"id":582,"slug":583,"hasResults":12,"nctId":584,"briefTitle":585,"officialTitle":586,"acronym":4,"eligibilityCriteria":587,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":588,"enrollmentInfo":589,"targetDuration":4,"studyType":23,"phases":591,"briefSummary":592,"conditions":593,"keywords":595,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":106},"100555523","eus-guided-response-assessment-to-nsbb-100555523","NCT06513195","EUS-guided Response Assessment to NSBB","Endoscopic Ultrasound Guided Response Assessment to Non-selective Beta-blockers in the Treatment of Clinically Significant Portal Hypertension","Inclusion Criteria:\n\n* Patients with a clinical and\u002For pathological diagnosis of compensated cirrhosis.\n* Patients with suspicion of CSPH and thus indication for NSBB treatment.\n* Patients not yet on NSBB therapy.\n* Patients willing and able to undergo repeated HVPG and EUS-guided pressure measurements as per protocol.\n\nExclusion Criteria:\n\nGeneral criteria\n\n* Patient is \\\u003C18 or \\>80 years of age\n* Patient is pregnant, breast-feeding or planning to become pregnant during the course of the study\n* Patient is unwilling or unable to sign the informed consent\n* Patients in whom general anesthesia or endoscopic procedures are contraindicated Medical criteria\n* Patients with cirrhosis and HCC Portopulmonary hypertension Portal or splanchnic venous thrombosis Prior TIPS Prior liver transplantation\n* Non-cirrhotic portal hypertension or pre-sinusoidal liver disease\n* Cholestatic liver disease with total bilirubin \\>3 mg\u002Fdl\n* Previous total or partial splenectomy\n* Known infection that is not controlled by medical intervention\n* Patients with contraindications for non-selective beta-blocker therapy, including but not limited to the following baseline vital signs:\n\nSystolic BP \\\u003C100 mmHg HR \\\u003C50 bpm\n\n* Patients with reduced life expectancy described by an ASA score of 4 or 5\n* INR \\>1.7 or platelet count \\\u003C50.000 per mm3\n* eGFR \\\u003C50 ml\u002Fmin\u002F1.73m2 (CKD-EPI formula) Anatomical criteria\n* Anatomical abnormalities that prevent access via EUS-guided puncture to the hepatic vein or intrahepatic portion of the portal vein, including anatomy that predisposes to difficult to reach puncture sites or an inadequate needle angle.\n* Visualization of ascites interposing the puncture tract on EUS\n* Diagnosis of portal vein thrombosis during EUS\n* Evidence of active gastrointestinal bleeding during EUS","80 Years",{"count":590,"type":22},24,[25],"The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.",[594],"Portal Hypertension Related to Cirrhosis",[596,597,598,599,600],"portal hypertension","EUS-PPG","HVPG","cirrhosis","non-selective beta blockers",{"date":602,"type":37},"2026-06-03",{"date":604,"type":37},"2024-07-17",{"date":606,"type":22},"2026-12",{"name":43,"class":44},{"id":609,"slug":610,"hasResults":12,"nctId":611,"briefTitle":612,"officialTitle":613,"acronym":614,"eligibilityCriteria":615,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":618,"briefSummary":619,"conditions":620,"keywords":622,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":632,"locationsCount":45},"100639637","improving-the-use-of-immunotherapy-to-treat-liver-cancer-100639637","NCT07623265","Improving the Use of Immunotherapy to Treat Liver Cancer","Optimizing and Improving Immunotherapy for Hepatocellular Carcinoma: the IO-MARC Study","IO-MARC","* General inclusion Criteria:\n\n  1. Male or female, age \\> 18 years\n  2. Diagnosis or suspected diagnosis of hepatocellular carcinoma based on imaging\n* Specific inclusion criteria cohort 1 (retrospective\u002Fprospective data may be applicable):\n\n  1. Pathologically confirmed HCC\n  2. Treated with systemic treatment \\[tyrosine kinase inhibitor (TKI) or immunotherapy (ICI)\\] in the last 7 years and follow-up data (at least one imaging on treatment) available until 01\u002F01\u002F2025\n  3. Biopsy obtained between 01\u002F01\u002F2018 until 01\u002F01\u002F2025\n  4. Left-over tissue from previous diagnostic biopsies or resection specimens available\n  5. Time between biopsy and initiation of systemic treatment \\\u003C 1 year\n  6. Ability to sign informed consent for secondary use of archival tissue and data collection for study-specific research for patients who are alive\n* Specific inclusion criteria cohort 2 (aHCC \\& prospective):\n\n  1. Suspicion of hepatocellular carcinoma (imaging criteria or recurrent disease of previously treated HCC)\n  2. Indication for tumor biopsy per standard of care\n  3. Eligible for systemic treatment (any) after pathological confirmation of HCC\n  4. Ability to sign informed consent for primary use of tissue and blood samples and data collection for study-specific research\n* Specific inclusion criteria cohort 3 (eHCC \\& prospective):\n\n  1. Suspicion of hepatocellular carcinoma (imaging criteria or recurrent disease of previously treated HCC)\n  2. Indication for local treatment (resection or ablation)\n  3. Ability to sign informed consent for primary use of tissue and blood samples and for data collection for study-specific research\n\n     Due to the observational nature of this study, participation in other (interventional) clinical trials is permitted, if biological materials can be collected per protocol.\n* General exclusion criteria:\n\n  1. Poor liver function and\u002For performance status which prohibits active treatment\n  2. Pathologically proven other malignancies of the liver, including primary cholangiocarcinoma or liver metastases\n  3. Treatment plan other than systemic treatment or local treatment (resection or ablation), such as TACE, TARE, liver transplantation",{"count":617,"type":22},300,[25],"This project targets patients with a form of primary liver cancer, specifically \"hepatocellular carcinoma\". This disease often develops in the context of a chronically diseased liver, caused by viral infections, excessive alcohol consumption, or fatty liver. Primarily due to the rise of the latter risk factor, liver cancer is one of the few cancer types whose incidence continues to increase globally, year after year. As a result, liver cancer has become the third most common cause of cancer-related deaths worldwide. There exists a significant challenge in reducing the disease on all fronts: prevention, diagnosis, and treatment.\n\nThis research aims to personalize the treatment of liver cancer patients, tailoring it to the individual. More specifically, this research seeks to identify patients with immunotherapy-sensitive liver cancer by biomarkers before treatment begins. Determining whether a tumor is immunotherapy-sensitive is internationally recognized as one of the most important challenges within this condition. Based on a combination of existing laboratory techniques on tumor tissue and\u002For blood, the investigators seek to predict the likelihood of this treatment's success before initiating it. With this knowledge, the investigators could recommend alternative treatments to patients with tumors that are unresponsive. This way, they would also avoid exposure to the side effects of an ineffective therapy.",[621],"Hepatocellular Carcinoma (HCC)",[623,624,625],"Biomarker","Hepatocellular carcinoma","Immunotherapy","2026-05-27",{"date":602,"type":37},{"date":629,"type":37},"2025-03-04",{"date":631,"type":22},"2032-01",{"name":43,"class":44},{"id":634,"slug":635,"hasResults":12,"nctId":636,"briefTitle":637,"officialTitle":638,"acronym":4,"eligibilityCriteria":639,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":4,"enrollmentInfo":640,"targetDuration":4,"studyType":23,"phases":642,"briefSummary":643,"conditions":644,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":646,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":45},"100493390","liquid-biopsies-in-esophageal-cancer-100493390","NCT05704530","Liquid Biopsies in Esophageal Cancer","Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study","Key inclusion criteria are:\n\n1. Male or female, age \\> 18 years\n2. New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC)\n3. Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable)\n4. Eligible for multidisciplinary treatment as assessed by MDT\n5. Able to provide informed consent (ICF) according to Good Clinical Practice and national\u002FEuropean regulations\n\nKey exclusion criteria are:\n\n1. (Oligo)metastatic disease\n2. Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…)\n3. Other active malignancies\n4. Previous exposure to chemoradiation (prior to MDT)\n5. Treatment plan after MDT: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)",{"count":641,"type":22},248,[25],"Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.",[645],"Esophageal Cancer",{"date":527,"type":37},{"date":648,"type":37},"2023-03-29",{"date":650,"type":22},"2029-12-31",{"name":43,"class":44},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":658,"eligibilityCriteria":659,"healthyVolunteers":12,"sex":54,"minAge":19,"maxAge":588,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":662,"conditions":663,"keywords":666,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":670,"lastUpdatePostDateStruct":671,"startDateStruct":673,"completionDateStruct":674,"leadSponsor":676,"locationsCount":106},"100618338","cares--customized-aftercare-report-for-evaluated-skin-cancer-patients-100618338","NCT07330323","CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients","Development and Evaluation of a Personalized Discharge Letter for Low-risk Skin Cancer Patients After Dermatological Screening.","CARES","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Low-risk skin cancer patients:\n\n  1. Negative personal history for melanoma\n  2. Less than 100 naevi\n  3. Less than 5 clinically atypical naevi\n  4. Maximum 1 BCC in history\n  5. Maximum 1 SCC, and at least 5 years ago\n  6. AK: treated and controlled with clinical response\n  7. M Bowen: treated and controlled with clinical response\n* Adult subjects (between 18 years of age and 80 years) at time of enrolment\n\nExclusion Criteria:\n\n* Presence of dermatological lesions requiring immediate treatment at the time of consultation.\n* History of solid organ transplantation (Organ Transplant Recipient, OTR).\n* Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).\n* Failure to meet one or more of the inclusion criteria.\n* Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.",{"count":497,"type":22},[25],"Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits.\n\nThis project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts .\n\nThe personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.",[664,665,479],"Management","Low Risk",[667,668,669],"Skin cancer risk and management","personalized discharge letter","low-risk skin cancer patients","2026-05-20",{"date":672,"type":37},"2026-05-22",{"date":670,"type":37},{"date":675,"type":22},"2029-06",{"name":43,"class":44},""]